Abstract 1772
Background
The mobile application is a valuable tool in the transmission of information in terms of having easy access in our daily lives and hosting applications containing information specific to many diseases. In a systematic analysis of the studies conducted on smartphones, it was determined that the method of using telephone in two studies was used, six people were reached via message and mobile application was used in five studies.
Methods
This systematic review is reported in line with the PRISMA. A total of 24 abstracts were retrieved through a systematic search for articles published in the six databases of PubMed, Cochrane CENTRAL Register of Controlled Trials, Ovid MEDLINE, Science Direct, ULAKBIM Turkish Medical Database, and Google Scholar. Only original resdearch articles included, in having a sample of health related mobile applications.
Results
Twenty four articles were chosen based on the inclusion criteria by researcher. The results of this review related that health related mobile applications. All articles states that health related mobile applications contribute to the individual and plays an important role in health development.
Conclusions
It is determined that researches about mobile health CARE applications in the world should be used in this subject. It can be said that the completed studies are small-sample and very specific, and that large-scale studies with larger samples can contribute significantly to future patient care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract